Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06293053 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
A Phase 3 study of Prurigo Nodularis, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 18
- Enrollment target
- 14
- Study locations
NCT06293053 is a Phase 3 study of Prurigo Nodularis that is actively recruiting participants, run by Sanofi. The registered enrollment target is 18 participants, below the 228-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (92% lower). The trial reports 14 study locations across 7 states.
The verdict
NCT06293053, a Phase 3 study of Prurigo Nodularis, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 18 participants
- Enrollment target
- 14
- Study locations
Study Summary
This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study. The study consists of 3 periods: * Screening period: 2 to 4 weeks. * Treatment period: 24 weeks. * Post-intervention follow-up period: 16 weeks. The study duration will be approximately 42 to 44 weeks for each participant (including screening, treatment, and follow-up periods). The total number of planned study visits for each participant will be 6.
Conditions Studied
Interventions
- DRUG Dupilumab
Study Locations (14)
Florida
- Pediatric Center of Excellence (PCE) - Miami Pediatric Endocrinology- Site Number : 8400005 - Coral Gables
- Life Clinical Trials - Coral Springs- Site Number : 8400018 - Coral Springs
- Direct Helpers Research Center- Site Number : 8400015 - Hialeah
- SunCoast Skin Solutions - Lutz- Site Number : 8400008 - Lutz
- USF Health- Site Number : 8400003 - Tampa
Texas
- Dell Children's Medical Center- Site Number : 8400007 - Austin
- Driscoll Children's Hospital- Site Number : 8400017 - Corpus Christi
- Texas Dermatology and Laser Specialists - San Antonio - Oakwell Court- Site Number : 8400020 - San Antonio
California
- Stanford University Medical Center CTRU - 800 Welch Road- Site Number : 8400021 - Palo Alto
- Mission Dermatology Center- Site Number : 8400011 - Rancho Santa Margarita
Minnesota
- Tareen Dermatology - Eagan- Site Number : 8400022 - Eagan
Missouri
- MediSearch Clinical Trials- Site Number : 8400004 - Saint Joseph
North Dakota
- AXIS Clinicals - Fargo- Site Number : 8400013 - Fargo
Oklahoma
- Vital Prospects Clinical Research Institute - Tulsa- Site Number : 8400002 - Tulsa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2024-05-15 |
| Est. Completion | 2027-11-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06293053
The ClinicalTrials.gov registry entry for NCT06293053 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 228-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (92% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prurigo Nodularis appearing as the primary indexed condition, and to 1 intervention - of which Dupilumab is the first listed.
NCT06293053 reports 14 study locations spanning 7 distinct geographic areas - top geographies include Florida, Texas, California.
Frequently Asked Questions
What is clinical trial NCT06293053 about?
NCT06293053 is a clinical study titled "A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis". This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study. The study consists of 3 periods: * Screening period: 2 to 4 weeks. * Treatment period: 24 weeks. * Post-intervention follow-up period: 16 weeks. The study duration will be approximately 42 to 44 weeks for each particip...
What is the current status of trial NCT06293053?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 18 participants. The study started on 2024-05-15. Estimated completion is 2027-11-03.
What conditions does trial NCT06293053 study?
This clinical trial studies the following conditions: Prurigo Nodularis.
What interventions are being tested in trial NCT06293053?
The interventions under investigation include: Dupilumab (DRUG).
Who is sponsoring clinical trial NCT06293053?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06293053 being conducted?
This trial has 14 study locations across California, Florida, Minnesota, Missouri, North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prurigo Nodularis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
RECRUITING · Phase 3
-
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
ACTIVE NOT RECRUITING · Phase 3
-
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
COMPLETED · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.